title: Difference in triptan effect in patients with migraine and early allodynia.
abstract: The aim of this study was to determine whether in migraine patients with and without aura early treatment with various triptans leads to differences in pain reduction after 1 h and in modulating cutaneous allodynia. Thirty-six patients with early manifestation of a clinically recognizable allodynia of the face and non-responders to earlier treatment with sumatriptan 100 mg were included. Patients were randomized to six triptan treatment groups. Significant pain reduction was seen only in the group receiving zolmitriptan nasal spray 5 mg with a mean visual analogue scale (VAS) score of 3.8 (s.d. 1.2) at baseline and 2.4 (s.d. 1.3; P = 0.015) at 1 h after using the triptan and was thus a predictor of a VAS score 3 within 1 h. The study results indicate that migraine headache intensity can be reduced within 1 h by using zolmitriptan 5 mg nasal spray in spite of the presence of early cutaneous allodynia.
authors.affiliation: Department of Neurology and Pain Medicine, Konventhospital Barmherzige Brüder, Linz, Austria. christian.lampl@bblinz.at
authors.forename: C
authors.initials: C
authors.lastname: Lampl
authors.forename: G
authors.initials: G
authors.lastname: Huber
authors.forename: S
authors.initials: S
authors.lastname: Haas
authors.forename: E
authors.initials: E
authors.lastname: Rittberger
authors.forename: H C
authors.initials: HC
authors.lastname: Diener
mesh_terms: D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D005145:Face / Q000294:innervation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020325:Migraine with Aura / Q000188:drug therapy*; D020326:Migraine without Aura / Q000188:drug therapy*; D023303:Oxazolidinones / Q000008:administration & dosage / Q000009:adverse effects; D010147:Pain Measurement; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D012867:Skin / Q000294:innervation; D020886:Somatosensory Disorders / Q000188:drug therapy*; D018170:Sumatriptan / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014276:Trigeminal Nerve; D014363:Tryptamines / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan; D018170:Sumatriptan